Liraglutide ameliorates non-alcoholic fatty liver disease by enhancing mitochondrial architecture and promoting autophagy through the SIRT1/SIRT3-FOXO3a pathway

详细信息    查看全文

• 作者：Wenxin Tong ; Liping Ju ; Miaoyan Qiu ; Qihai Xie ; Ying Chen ; Weili Shen ; Weihong Sun ; Weiqing Wang and Jingyan Tian
• 刊名：Hepatology Research
• 出版年：2016
• 出版时间：August 2016
• 年：2016
• 卷：46
• 期：9
• 页码：933-943
• 全文大小：931K
• ISSN：1872-034X

文摘

Overwhelming oxidative stress is implicated as crucial in the pathogenesis of non-alcoholic fatty liver disease (NAFLD). Liraglutide, a well-established antidiabetes drug, was recently reported to ameliorate NAFLD with an elusive mechanism. We used a mouse model to examine whether liraglutide could ameliorate NAFLD and explored the possible mechanisms.